Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07101328 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 215
- Enrollment target
NCT07101328 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 215 participants.
The verdict
NCT07101328, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 215 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Interventions
- DRUG LY4152199 - IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07101328
The ClinicalTrials.gov registry entry for NCT07101328 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY4152199 - IV is the first listed.
NCT07101328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07101328 about?
NCT07101328 is a clinical study titled "A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )". The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
What is the current status of trial NCT07101328?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2026-05-28. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07101328?
The interventions under investigation include: LY4152199 - IV (DRUG).
Who is sponsoring clinical trial NCT07101328?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.